Clinical trial
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating…
NCT00093444 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00093444 |
|---|---|
| Title | Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors |
| Official title | A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Liver Cancer, Metastatic Cancer |
| Intervention type | Drug, Procedure |
| Interventions | lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation |
| Enrollment | 30 |
| Start date | Sep 1, 2004 |
| Completion | Jan 1, 2010 |
| First posted | Oct 8, 2004 |
| Last update posted | Mar 15, 2012 |
| Countries | China, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: